A 2026 survey compares women’s intimate-health priorities with executives’ commercial focus. Read the findings and their limits for midlife care.
On September 23, 2026, AlixPartners and Cosmetic Executive Women (CEW) published The Extract: Beauty × Health × Wellness 2026, a survey report comparing consumer priorities with executives’ views of commercial opportunities. Its women’s-health findings identified vaginal and intimate health and low libido and sexual health as areas respondents viewed as underserved or underrepresented.
AlixPartners places the findings against a backdrop of investment and celebrity attention around menopause care. The announcement challenges the idea that commercial attention to menopause necessarily reflects attention to the full range of women’s health priorities. This is a challenge to commercial framing rather than a revision of medical standards.
That distinction matters for midlife readers. Menopause is a relevant subject for this audience. Yet a broad menopause label and a specific question about vaginal comfort or sexual desire are not interchangeable. The useful editorial question is whether the wider conversation makes room for the concerns women themselves want addressed.
The report points toward a more specific discussion of women’s wellness. Rather than using the visibility of one category as a stand-in for the whole picture, its findings invite closer attention to the individual topics within that picture.
According to AlixPartners, the online survey was conducted between May and June 2026. It included 1,000 consumers ages 18 and older and 127 beauty, health and wellness executives. The consumer sample was 51% women and 49% men.
Beauty Independent’s account of the report sets out three comparisons between women’s health priorities and executives’ commercial priorities:
The direction of the comparisons differs by topic. Women’s reported interest in vaginal and intimate health and low libido and sexual health exceeded executives’ reported commercial interest. For perimenopause and menopause, the executive figure was higher than the women’s figure.
AlixPartners’ own announcement describes vaginal and intimate health as underserved and low libido and sexual health as underrepresented. The executive percentages above come from Beauty Independent’s separate account. Keeping those attributions distinct preserves the difference between the primary announcement and the more detailed comparison reported in the coverage.
CEW describes The Extract as a proprietary report intended to identify where consumer priorities and executive investment diverge. Its purpose is to examine how the beauty, health and wellness industry’s view of opportunity relates to what consumers say matters to them.
Beauty Independent describes the report’s wellness category as including sexual wellness alongside mental health and sleep. Nutrition, fitness and stress also sit within that broader scope. Sexual wellbeing is therefore part of the report’s wider wellness discussion rather than a separate clinical investigation.
For Refemina, that breadth supports a whole-person editorial approach. Desire and intimate comfort belong in the same adult conversation as other aspects of midlife health. They do not need to become the only subject of that conversation, but neither should they disappear inside a broad label that leaves the specific concern unnamed.
The useful question is not which category deserves the strongest marketing message. It is whether the language of women’s wellness reflects the range of priorities women are expressing.
The findings describe surveyed respondents’ views at a particular point in 2026. They do not establish whether these gaps have widened or narrowed over time. The consumer sample covered adults broadly, and the published reporting provides no intimate-health results separated by age or menopausal stage. The percentages should not be presented as findings specifically about midlife or postmenopausal women.
The comparison also places different measures side by side: women’s priority health topics and executives’ top commercial opportunities. Those measures are related but not identical. They are not an independent account of actual spending, the prevalence of health problems, access to care or treatment outcomes.
The AlixPartners announcement does not supply the underlying question wording or formal definitions of terms such as “underserved” and “priority.” It also does not provide the response options or detailed women’s-health tables. That limits how precisely readers can interpret what each response meant beyond the published descriptions.
Finally, the report does not establish that menopause investment caused intimate-health priorities to receive less attention. It does not identify the causes of changes in desire or comfort or evaluate treatments. These findings are a reason to ask better questions, not a basis for diagnosis or an individual care decision.
The practical implication is to bring intimate and sexual wellbeing into a midlife health discussion on their own terms. A broad question about menopause and a focused question about desire or vaginal comfort can sit together. Neither needs to replace the other.
When discussing a concern with a qualified clinician, readers can describe what they want help with and ask which options or referrals are appropriate. The starting point is the concern itself. It does not have to arrive packaged in the same language used by a wellness campaign or product category.
A useful conversation can distinguish a question about desire from a question about comfort. It can also make room for a reader whose main priority is understanding a change rather than choosing a treatment. The survey’s categories offer language for opening that discussion without defining its outcome.
Refemina’s discussion of bringing sexual wellbeing into midlife care provides a broader editorial context for that approach. The point is to give the subject a clear place in the conversation rather than expecting it to be covered automatically whenever menopause is mentioned.
This is not a demand to medicalise every intimate change. It is a way of keeping women’s stated concerns visible. The goal of the conversation should remain specific to the person: understanding the concern and identifying what kind of professional support is appropriate.
The survey creates a reason to question market messaging before treating it as a route to personal care. A commercial category tells readers how an industry groups an opportunity. A useful health conversation asks what the individual concern is and what information is needed to address it.
For a midlife reader, the practical question is more precise than whether a product is marketed for menopause. It is whether the information being offered addresses her actual question about desire or comfort. Personal treatment decisions belong with qualified care rather than with a survey ranking or a category label.
The research also supports caution around claims that one hormone explains every change in intimacy. A clear editorial response is to ask what evidence supports the proposed explanation before accepting it as the answer. That keeps the question open for appropriate assessment without turning uncertainty into a shopping problem.
Readers can apply the same evidence-first approach to questions that come before an intimate-health supplement purchase. Naming a concern is the beginning of understanding it. It is not a commitment to a product or to a single explanation.
The comparison should not become an argument for taking attention away from menopause care. Its more useful implication is that commercial visibility and women’s expressed priorities deserve to be examined separately. Recognising vaginal health and sexual wellbeing does not require treating menopause as an unimportant subject.
Nor should the survey ranking become a ranking of what an individual woman ought to care about. A woman whose main concern is menopause deserves a substantive conversation about it. A woman whose priority is desire or intimate comfort deserves the same seriousness without having to translate that concern into a broader market category.
The editorial lesson is to make the language more precise. “Women’s wellness” should leave room for specific questions rather than settling them in advance. For this audience, that means keeping hormonal change in view while allowing sexual wellbeing and comfort to be discussed directly.
Going forward, the most useful clinical response to this survey is to let women’s specific questions about desire and comfort guide the conversation rather than letting commercial categories set its boundaries.
Clearer language for a concern about desire or comfort gives an intimate-health conversation a concrete focus. When such questions are ignored or sensationalised, Refemina translates credible research into adult guidance that places sexual wellbeing alongside confidence and the broader experience of hormonal change.
Follow Refemina for research-led insights on menopause, strength, metabolism, nutrition, skin, intimacy and confidence through midlife. New articles turn complex topics into clear, useful context.
Keep learning about the changes that shape energy, strength, confidence and wellbeing through midlife.
Explore Resources